RANI vs. URGN, PGEN, MREO, VTYX, NATR, ATAI, NLTX, FBLG, EPIX, and ESPR
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include UroGen Pharma (URGN), Precigen (PGEN), Mereo BioPharma Group (MREO), Ventyx Biosciences (VTYX), Nature's Sunshine Products (NATR), Atai Life Sciences (ATAI), Neoleukin Therapeutics (NLTX), FibroBiologics (FBLG), ESSA Pharma (EPIX), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical preparations" industry.
UroGen Pharma (NASDAQ:URGN) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
UroGen Pharma presently has a consensus target price of $46.67, indicating a potential upside of 234.05%. Rani Therapeutics has a consensus target price of $11.50, indicating a potential upside of 74.77%. Given Rani Therapeutics' higher possible upside, equities research analysts plainly believe UroGen Pharma is more favorable than Rani Therapeutics.
Rani Therapeutics has a net margin of 0.00% compared to Rani Therapeutics' net margin of -123.61%. Rani Therapeutics' return on equity of 0.00% beat UroGen Pharma's return on equity.
Rani Therapeutics has lower revenue, but higher earnings than UroGen Pharma. Rani Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
UroGen Pharma has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
UroGen Pharma received 330 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Rani Therapeutics an outperform vote while only 73.13% of users gave UroGen Pharma an outperform vote.
91.3% of UroGen Pharma shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 11.1% of UroGen Pharma shares are owned by company insiders. Comparatively, 50.0% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, UroGen Pharma and UroGen Pharma both had 2 articles in the media. Rani Therapeutics' average media sentiment score of 0.92 beat UroGen Pharma's score of 0.27 indicating that UroGen Pharma is being referred to more favorably in the media.
Summary
UroGen Pharma and Rani Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rani Therapeutics Competitors List
Related Companies and Tools
